Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Thalassemia × Alemtuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia 12 Leukemia, Lymphocytic, Chronic, B-Cell 10 Lymphoma 7 Lymphoma, Non-Hodgkin 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Myelodysplastic Syndromes 5 Myeloproliferative Disorders 4 Hodgkin Disease 4 Multiple Myeloma 3 Lymphoma, Follicular 3 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3 Hematologic Neoplasms 3 Neoplasms, Plasma Cell 2 Lymphoma, T-Cell 2 Lymphoma, Mantle-Cell 2 Lymphoma, Large B-Cell, Diffuse 2 Leukemia, Myeloid, Chronic-Phase 2 Leukemia, Myeloid, Acute 2 Hematologic Diseases 2 Graft vs Host Disease 2 Congenital Abnormalities 2 Anemia, Aplastic 2 Waldenstrom Macroglobulinemia 1 Unrecognized Condition: Mature B or T-cell Neoplasm 1 Thrombocythemia, Essential 1 Thalassemia 1 Primary Myelofibrosis 1 Preleukemia 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1

Interventions

fludarabine phosphate 2 Cyclophosphamide 2 fludarabine 1 Whole-Body Irradiation 1 Peripheral Blood Stem Cell Transplantation 1 Mesna 1 Busulfan 1 Alemtuzumab 1 AP 1903 reagent 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00578292 2020-05-01

THALLO

Baylor College of Medicine

Phase NA Terminated

10 enrolled 15 charts

Lymphoma, Follicular, Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡